Who’s OnlineThere are no users currently online
- Patients Sickle cell disease Healthcare financing Drugs and diagnostics Urban health Social determinants Environmental and non health sector policies Vulnerable groups Disabilities Public-private partnerships Cancer Diabetes Tuberculosis Physiotherapy Emergencies Research and education New roles and responsibilities of health personnel Lifestyle Hypertension Cardiovascular diseases Elderly Bioethics Patient Safety GIS Healthcare Family Medicine Occupational medicine Gender Surgery Respiratory chronic diseases Obesity Non-communicable chronic diseases Healthcare delivery Youth Refugees Primary health care Information and communication technology mHealth social accountability Malaria Migration Foreign policy Equity and empowerment Redesigning health services Community participation Nursing Tropical neglected diseases Civil society Capacity building HIV/AIDS Vaccines Physical activity Health information and technologies Mental health Communicable chronic diseases Tobacco Prevention and infection control E-health Hepatitis self-management
Abstract and Sessions by Thematic Tracks (work in progress)
- GHF2006 – PS03 – Most Neglected Diseases on Alternative Approaches to New Drug Development: Two R&D Initiatives
- GHF2006 – PS11 – Public-Private Partnerships: Beneficial or Undermining? on From Basic Research to Drug Delivery: When are PPPS Needed?
- Mako on Children’s Health in Ecologically Polluted Regions: Georgia
- DR: Sohair Abdulla on Adherence to the Diabetics and Hypertensive Treatment Guidelines for Health Workers in Health Facilities: Ibadan, Nigeria
- Hein39 on Affordable Diabetes Care: Cambodia
Posted on 12/11/2012 | No CommentsEven though one out of 10 Pakistanis suffers from the virus of either Hepatitis B or C, the hepatitis-infected population of 15 million awaits the proper implementation of a National Programme for Prevention and Control of Hepatitis in Pakistan to control the deadly disease.
Posted on 10/01/2012 | No CommentsChronic hepatitis B infection affects 350 million people worldwide, of which 50 million are in Africa. In sub-Saharan Africa, where the disease is endemic, the population of some of these countries has a prevalence reaches 98% for markers of infection for hepatitis B virus (HBV).
Response of Patients with Chronic Hepatitis C to Interferon and Ribavirin Combination Therapy: an Experience from PakistanPosted on 20/12/2011 | No CommentsHepatitis C virus infection is the major cause of chronic hepatitis in Pakistan. The aim of this study was to determine the response of patients with chronic hepatitis C to interferon and ribavirin combination therapy as initial treatment in our setup.